{"id":756,"date":"2026-09-01T16:45:45","date_gmt":"2026-09-01T16:45:45","guid":{"rendered":"https:\/\/nhdbio.com\/resources\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/"},"modified":"2026-09-01T16:45:45","modified_gmt":"2026-09-01T16:45:45","slug":"pt-141-bremelanotide-free-base-acetate-finished-drug-boundary","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/de\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/","title":{"rendered":"PT-141\/Bremelanotid: Grenze f\u00fcr freie Base, Acetat und fertiges Arzneimittel"},"content":{"rendered":"<p class=\"pim-standfirst wp-block-paragraph\">PT-141 ist der Entwicklungscode f\u00fcr Bremelanotid. Ein Peptid mit freier Base, seine Acetatform und die genehmigte fertige Injektion sind verwandte Datens\u00e4tze, aber keine austauschbaren Materialien.<\/p><div class=\"wp-block-group pim-key-takeaways\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 class=\"wp-block-heading\">Beweise auf einen Blick<\/h2><ul class=\"wp-block-list\"><li>PubChem listet die freie Base von Bremelanotid als zyklisches Peptid mit sieben Resten und einem Molekulargewicht von 1025.2 g\/mol auf.<\/li><li>DailyMed listet Bremelanotidacetat als den Inhaltsstoff auf, der 1.75 mg Bremelanotid in 0.3 ml des zugelassenen Fertigprodukts liefert.<\/li><li>Die beh\u00f6rdliche Zulassung gilt f\u00fcr die genannte Formulierung, den Hersteller und die Kennzeichnung \u2013 nicht f\u00fcr jedes Material, das PT-141 als Synonym verwendet.<\/li><\/ul><\/div><\/div><figure class=\"wp-block-image size-full pim-article-figure\"><img loading=\"lazy\" decoding=\"async\" width=\"1672\" height=\"941\" src=\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-identity-boundary.webp\" alt=\"Analytische Unterscheidung zwischen PT-141 freier Base, Acetat und Fertigformulierung\" class=\"wp-image-740\" srcset=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-identity-boundary.webp 1672w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-identity-boundary-300x169.webp 300w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-identity-boundary-1024x576.webp 1024w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-identity-boundary-768x432.webp 768w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-identity-boundary-1536x864.webp 1536w\" sizes=\"auto, (max-width: 1672px) 100vw, 1672px\" \/><figcaption class=\"wp-element-caption\">Originale redaktionelle analytische Illustration. Es stellt kein geliefertes Produkt, keine freigegebene Charge, keine genehmigte Formulierung, kein Testergebnis oder keine klinische Verwendung dar.<\/figcaption><\/figure><h2 class=\"wp-block-heading\">Identit\u00e4tsdatensatz<\/h2><p class=\"wp-block-paragraph\">Der PubChem-Peptiddatensatz enth\u00e4lt eine N-acetylierte zyklische Sequenz mit einem D-Phenylalaninrest. Sequenzreihenfolge, Cyclisierung und Stereochemie tragen alle zur Identit\u00e4t bei; ein kurzer Marketingname erfasst sie nicht.<\/p><div class=\"wp-block-group pim-evidence-table\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><div class=\"pim-evidence-row\"><strong>Forschungscode<\/strong><span>PT-141<\/span><\/div><div class=\"pim-evidence-row\"><strong>Aktive Einheit<\/strong><span>Bremelanotid; PubChem CID 9941379<\/span><\/div><div class=\"pim-evidence-row\"><strong>Fertigarzneimittelbestandteil<\/strong><span>Bremelanotidacetat<\/span><\/div><div class=\"pim-evidence-row\"><strong>Identit\u00e4tspr\u00fcfungen<\/strong><span>Zyklische Sequenz, Stereochemie, Gegenion, Masse, Chromatographie, Inhalt und Chargenverkn\u00fcpfung<\/span><\/div><\/div><\/div><h2 class=\"wp-block-heading\">Analyse- und Beweisgrenze<\/h2><p class=\"wp-block-paragraph\">Der Acetatgehalt ver\u00e4ndert die Formelgewichts- und Inhaltsberechnungen. In einem Zertifikat sollte angegeben werden, ob das Ergebnis auf der Basis der freien Base, des Acetats oder im Ist-Zustand gemeldet wird.<\/p><p class=\"wp-block-paragraph\">Nutzen Sie niemals die Vyleesi-Indikation oder das Sicherheitsprofil als Beweis daf\u00fcr, dass eine Katalogcharge therapeutisch gleichwertig ist. Die entsprechende Verbindung ist eine Evidenz-Kontext-Verbindung mit einer markanten Grenze zwischen fertigem Arzneimittel.<\/p><h2 class=\"wp-block-heading\">Redaktionelle Regel<\/h2><p class=\"wp-block-paragraph\">Geben Sie das genaue Material, die Form, das Modell oder die Population und den Endpunkt an, die durch den zitierten Datensatz unterst\u00fctzt werden. Wandeln Sie keine mechanistische Plausibilit\u00e4t, ein Tierergebnis, ein Etikett eines Fertigarzneimittels oder einen analytischen Test in eine Aussage \u00fcber eine nicht verwandte Katalogcharge um.<\/p>","protected":false},"excerpt":{"rendered":"<p>PT-141 ist der Entwicklungscode f\u00fcr Bremelanotid. Ein Peptid mit freier Base, seine Acetatform und die genehmigte fertige Injektion sind verwandte Datens\u00e4tze, aber keine austauschbaren Materialien.<\/p>","protected":false},"author":1,"featured_media":740,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"358","pim_article_type":"Evidence and material-quality guide","pim_evidence_level":"FDA label plus curated chemical and peptide identity records","pim_reviewer":"Site evidence editorial team","pim_reviewed_date":"2026-09-02","pim_editorial_note":"Source-checked on 2026-09-02. Null results, study size, model\/population limits and relevant conflicts are retained. This is not medical advice, a customer case or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"Primary\/regulatory sources, factual claims, numerical results, limitations and product-evidence boundary checked for batch 3.","pim_creation_method":"The editorial workflow began with linked PubMed primary papers, systematic reviews, PubChem identity records and FDA\/DailyMed regulatory records. Population or model, denominators, endpoints, numerical results, null findings, limitations and conflicts were extracted before drafting. AI-assisted drafting and original image generation were used; the final facts and evidence boundaries were checked against the linked records on 2026-09-02. This is not independent peer review.","pim_sources":"[{\"title\":\"RECONNECT bremelanotide phase 3 trials\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31599840\/\",\"note\":\"Primary phase 3 publication; PMID 31599840.\"},{\"title\":\"DailyMed Vyleesi prescribing information\",\"url\":\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf\",\"note\":\"Current FDA-approved finished-drug label.\"},{\"title\":\"PubChem Bremelanotide record\",\"url\":\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Bremelanotide\",\"note\":\"Free-base peptide identity; CID 9941379.\"}]","footnotes":""},"categories":[20],"tags":[],"class_list":["post-756","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-quality-guides"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>PT-141\/Bremelanotide: Free Base, Acetate and Finished-Drug Boundary<\/title>\n<meta name=\"description\" content=\"PT-141 is the development code associated with bremelanotide. A free-base peptide, its acetate form and the approved finished injection are related records\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/de\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PT-141\/Bremelanotide: Free Base, Acetate and Finished-Drug Boundary\" \/>\n<meta property=\"og:description\" content=\"PT-141 is the development code associated with bremelanotide. A free-base peptide, its acetate form and the approved finished injection are related records\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/de\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T16:45:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-identity-boundary.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"PT-141\\\/Bremelanotide: Free Base, Acetate and Finished-Drug Boundary\",\"datePublished\":\"2026-09-01T16:45:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/\"},\"wordCount\":263,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-identity-boundary.webp\",\"articleSection\":[\"Evidence &amp; Quality Guides\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/\",\"name\":\"PT-141\\\/Bremelanotide: Free Base, Acetate and Finished-Drug Boundary\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-identity-boundary.webp\",\"datePublished\":\"2026-09-01T16:45:45+00:00\",\"description\":\"PT-141 is the development code associated with bremelanotide. A free-base peptide, its acetate form and the approved finished injection are related records\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-identity-boundary.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-identity-boundary.webp\",\"width\":1672,\"height\":941,\"caption\":\"AI-generated illustration: Analytical distinction among PT-141 free base, acetate and finished formulation\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PT-141\\\/Bremelanotide: Free Base, Acetate and Finished-Drug Boundary\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/de\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"PT-141\/Bremelanotid: Grenze f\u00fcr freie Base, Acetat und fertiges Arzneimittel","description":"PT-141 ist der Entwicklungscode f\u00fcr Bremelanotid. Ein Peptid mit freier Base, seine Acetatform und die genehmigte fertige Injektion sind verwandte Aufzeichnungen\u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/de\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/","og_locale":"de_DE","og_type":"article","og_title":"PT-141\/Bremelanotide: Free Base, Acetate and Finished-Drug Boundary","og_description":"PT-141 is the development code associated with bremelanotide. A free-base peptide, its acetate form and the approved finished injection are related records\u2026","og_url":"https:\/\/nhdbio.com\/de\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/","og_site_name":"NHD","article_published_time":"2026-09-01T16:45:45+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-identity-boundary.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Verfasst von":"NHD Technical Team","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"PT-141\/Bremelanotide: Free Base, Acetate and Finished-Drug Boundary","datePublished":"2026-09-01T16:45:45+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/"},"wordCount":263,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-identity-boundary.webp","articleSection":["Evidence &amp; Quality Guides"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/","url":"https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/","name":"PT-141\/Bremelanotid: Grenze f\u00fcr freie Base, Acetat und fertiges Arzneimittel","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-identity-boundary.webp","datePublished":"2026-09-01T16:45:45+00:00","description":"PT-141 ist der Entwicklungscode f\u00fcr Bremelanotid. Ein Peptid mit freier Base, seine Acetatform und die genehmigte fertige Injektion sind verwandte Aufzeichnungen\u2026","breadcrumb":{"@id":"https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-identity-boundary.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-identity-boundary.webp","width":1672,"height":941,"caption":"AI-generated illustration: Analytical distinction among PT-141 free base, acetate and finished formulation"},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"PT-141\/Bremelanotide: Free Base, Acetate and Finished-Drug Boundary"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Peptidrohstoffe und individuelle Peptidsynthese","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"NHD Technisches Team","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"Das technische Team von NHD verwaltet Katalogdokumentationen und Beweiszusammenfassungen f\u00fcr Forschungszwecke. Rezensierte Artikel verweisen auf von Experten begutachtete Artikel, Studienregister und beh\u00f6rdliche Aufzeichnungen, behalten Nullergebnisse und Studieneinschr\u00e4nkungen bei und unterscheiden ver\u00f6ffentlichte Interventionen von Katalogmaterialien. F\u00fcr die Strukturierung kann AI-unterst\u00fctztes Zeichnen verwendet werden; Quellenverkn\u00fcpfungen und Beweisgrenzen bleiben sichtbar. Bei dieser Arbeit handelt es sich nicht um eine unabh\u00e4ngige Begutachtung oder medizinische Beratung.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/de\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/756","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/comments?post=756"}],"version-history":[{"count":0,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/756\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media\/740"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media?parent=756"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/categories?post=756"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/tags?post=756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}